UNITED STATES                                  
                       SECURITIES AND EXCHANGE COMMISSION                       

                             Washington, D.C. 20549                             
                          ____________________________                          
                                                                                
                                  SCHEDULE 14A                                  
                  Proxy Statement Pursuant to Section 14(a) of                  
                      the Securities Exchange Act of 1934                       
                          ____________________________                          

                                                                               
Filed by the Registrant         Filed by a party other than the Registrant     


Check the appropriate box:

                                                                                       
      Preliminary Proxy Statement                                                      
                                                                                       
      Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  
                                                                                       
      Definitive Proxy Statement                                                       
                                                                                       
      Definitive Additional Materials                                                  
                                                                                       
      Soliciting Material under (s) 240.14a-12                                         

                                 EHEALTH, INC.                                  
                (Name of Registrant as Specified in Its Charter)                

    (Name of Person(s) Filing Proxy Statement, if Other than the Registrant)    

Payment of Filing Fee (Check all boxes that apply):

                                                                                                                  
      No fee required.                                                                                            
                                                                                                                  
      Fee paid previously with preliminary materials.                                                             
                                                                                                                  
                                                                                                                  
                                                                                                                  
                                                                                                                  
                                                                                                                  
                                                                                                                  
      Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.        
                                                                                                                  
                                         
                                                                                                                  
                                                                                                                  
                                                                                                                  
                                                                                                                  



  
  



-------------------------------------------------------------------------------

                       13620 Ranch Road 620 N, Suite A250                       
                                Austin, TX 78717                                
                                 (737) 248-2340                                 
                                                                    May 23, 2024
Dear Fellow Stockholder:

I am writing to you to seek your support of our proposal to approve the new 
2024 Equity Incentive Plan (the "Plan"), which will replace our 2014 Equity 
Incentive Plan that is set to expire on June 12, 2024. If the Plan is approved 
by our stockholders, an additional 1.35 million shares will be reserved for 
issuance under the Plan. The passing of this proposal is critical to our 
successful strategy execution as we work towards sustainable profitable growth 
and cash flow generation and establishing eHealth as a gold standard in health 
insurance distribution.
In April of 2022, with these goals in mind, we launched a business 
transformation plan that included overhauling our sales and marketing 
organizations, further streamlining the consumer experience on our platform, 
and rationalizing our cost structure. During 2022 and 2023, we achieved a $76 
million cumulative improvement to our net income (loss), a $37 million 
cumulative improvement to our adjusted EBITDA and a $156 million cumulative 
improvement to our operating cash flow. In the fourth quarter of 2023, we 
resumed revenue and member enrollment growth on this enhanced operational 
foundation. On May 7 of this year, we shared another execution update with our 
investors as part of our first quarter 2024 earnings report. In the first 
quarter of 2024, eHealth continued to demonstrate significant progress across 
many of our key financial and operational metrics including revenue and 
enrollment growth, profitability, cash flow and business diversification.

As part of our transformation plan, I reconstituted eHealth's senior 
leadership team (SLT) with seven of the ten members of our current SLT 
recruited in 2022 and 2023. Providing competitive total compensation, 
including the equity incentive component, was critical to recruiting and 
rewarding this leadership team. It is important to note that given the past 
executive turnover and resulting cancellation of unvested equity grants of 
departed executives, our net burn rate, which we believe is a truer reflection 
of our use of equity compensation in recent years, is well below our gross 
burn rate
1
. Specifically, our net burn rates in 2022 and 2023 were 3.6% and 8.4% 
compared to gross burn rates of 8.9% and 9.8%, demonstrating the effects of 
this transformation period on our granting practices [
E
xhibit
1
]. We expect our equity burn rates to normalize in 2024.
At the end of 2023, we communicated that the major components on the 
transformation plan were completed. As part of our investor presentation 
published on May 13, 2024, which is available on our investor relations 
website, we disclosed our ambitious three-year goals calling for strong 
revenue CAGR accompanied by adjusted EBITDA margin expansion and positive free 
cash flow growth
2
. I strongly believe that our ability to provide equity grants, including 
performance-based equity, is important to retain and attract leadership and 
management and to execute on the previously stated goals while maintaining 
full alignment of our employee and stockholder interests. Going forward, we 
plan to shift a greater percentage of our equity compensation towards 
performance-based equity awards to help achieve even greater alignment between 
our strategic goals and compensation.
Our focus on "at-risk" equity compensation is not limited to the SLT members 
and, in fact, goes deep within our organization. This is in line with best 
practices in our industry
-
the healthcare IT and the broader technology
1
Gross burn rate was calculated as the total of equity awards granted during 
the fiscal year, divided by the weighted average number of shares outstanding. 
Net burn rate was calculated as equity awards granted during the fiscal year 
less equity awards cancelled and returned to the plan, divided by the weighted 
average number of shares outstanding.
2
The reference to the investor presentation and information contained therein 
are intended to be "furnished" and shall not be deemed "filed" for purposes of 
Section 18 of the Securities Exchange Act of 1934, as amended. Except as shall 
be expressly set forth by specific reference in such filing, the reference to 
the investor presentation and information contained therein shall not be 
incorporated by reference into any filing with the Securities and Exchange 
Commission made by the Company, whether made before or after the date hereof, 
regardless of any general incorporation language in such filing.

-------------------------------------------------------------------------------

sector. eHealth's annual burn rates and overall dilution from equity-based 
compensation is in line with that of our Proxy peers. It is important to note 
that ISS compares eHealth to the appropriate peer group for the purpose of 
evaluating our executive compensation. However, when evaluating our equity 
plan, ISS uses a different set of peer group companies consisting of firms in 
our GICS industry group
-
typically regional financial services companies that do not compete for the 
same talent pool as eHealth and are subject to different compensation 
practices.
Without additional shares available for issuance under an equity incentive 
plan, we would likely be compelled to increase the cash component of employee 
compensation to remain competitive, which runs directly counter to our core 
objective of maximizing cash flow generation. Further, our ability to maintain 
a stable and committed team of management becomes challenging without the 
benefits of sufficient equity that vests over multiple years. Our Board of 
Directors unanimously recommends that you vote "
FOR
" the approval of Proposal 4
-
the adoption of the proposed Plan. Thank you for your consideration and 
anticipated support.

                                         
   Sincerely yours,                      
                                         
                                         
                                         
   Francis S. Soistman                   
   Chief Executive Officer and Director  

Forward-Looking Statements

This letter to our stockholders from our Chief Executive Officer contains 
statements that are forward-looking statements as defined within the Private 
Securities Litigation Reform Act of 1995. These include statements regarding 
our expectations regarding our business, operations and strategy; the impact 
of our business transformation plan on our business and our future cost 
reduction efforts; the effect of our marketing and branding efforts on our 
business; our financial prospects and outlook; future stockholder value; 
expected growth and value creation; the expected impact of a new equity plan 
on our ability to hire and retain our workforce; our expected equity burn rate 
in 2024; cost reductions and efficiencies; priorities and performance; and 
other statements regarding our future operations, financial condition, 
prospects and business strategies.
These forward-looking statements are inherently subject to various risks and 
uncertainties that could cause actual results to differ materially from the 
statements made, including the risks and uncertainties described in our most 
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with 
the Securities and Exchange Commission (SEC) and available on the Investor 
Relations page of our website at https://ir.ehealthinsurance.com and on the 
Securities and Exchange Commission's website at www.sec.gov. In particular, we 
are required by Accounting Standards Codification 606 -
Revenue from Contracts with Customers
to make numerous assumptions that are based on historical trends and our 
management's judgment. These assumptions may change over time and have a 
material impact on our revenue recognition, guidance, and results of 
operations. Please review the assumptions stated in this communication 
carefully. All forward-looking statements in this letter are based on 
information available to us as of the date hereof, and we do not assume any 
obligation to update the forward-looking statements provided to reflect events 
that occur or circumstances that exist after the date on which they were made, 
except as required by law.

Non-GAAP Information

This letter to our stockholders from our Chief Executive Officer includes 
adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is calculated 
by excluding dividends for preferred stock and change in preferred stock 
redemption value, provision for (benefit from) income taxes, depreciation and 
amortization, stock-based compensation expense, amortization of intangible 
assets, impairment, restructuring and other charges, interest expense, other 
income (expense), net, and other non-recurring charges from GAAP net income 
(loss) attributable to common stockholders. Other non-recurring charges to 
GAAP net income (loss) attributable to common stockholders may include 
transaction expenses in connection with capital raising transactions (whether 
debt, equity or equity-linked) and acquisitions, whether or not consummated, 
purchase price adjustments and the cumulative effect of a change in accounting 
principles.

The presentation of non-GAAP financial information is not intended to be 
considered in isolation or as a substitute for results prepared in accordance 
with GAAP. A reconciliation of adjusted EBITDA to GAAP net income (loss) 
attributable to common stockholders, the most directly comparable GAAP 
financial measure, is available in the Appendix to this letter. Management 
uses both GAAP and non-GAAP information in evaluating and operating its 
business internally and as such has determined that it is important to provide 
this information to investors.

-------------------------------------------------------------------------------


Additional Information and Where to Find It

eHealth has filed with the SEC a definitive proxy statement on Schedule 14A, 
with respect to its solicitation of proxies for eHealth's 2024 Annual Meeting 
of Stockholders. Investors and stockholders are urged to read the proxy 
statement (including any amendments or supplements thereto) filed with the SEC 
carefully and in their entirety because they contain or will contain important 
information about any solicitation. Investors and stockholders may obtain 
copies of these documents and other documents filed with the SEC by eHealth 
free of charge at www.proxyvote.com/EHTH. Copies of the documents filed by 
eHealth are also available on the Investor Relations page of our website at 
ir.ehealthinsurance.com and on the Securities and Exchange Commission's 
website at www.sec.gov.


-------------------------------------------------------------------------------

                                                                       Exhibit 1




-------------------------------------------------------------------------------


{graphic omitted}
{graphic omitted}
{graphic omitted}
{graphic omitted}